SCHEMBL1225864

SCHEMBL1225864

C=C(C)C(=O)OC(C)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
ADRA1D P25100 1/20 0.50
PTAFR P25105 1/20 0.50
HTR1D P28221 1/20 0.50
HTR2C P28335 1/20 0.50
ADRA1B P35368 1/20 0.50
DRD3 P35462 1/20 0.50
TMEM97 Q5BJF2 1/20 0.50
MAPT P10636 3/20 0.47
NR5A2 O00482 1/20 0.46
NR5A1 Q13285 1/20 0.46
PLA2G10 O15496 1/20 0.44
LMNA P02545 4/20 0.43
AKT1 P31749 2/20 0.43
ESR1 P03372 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CDC25A P30304 1/20 0.43
AGTR1 P30556 1/20 0.43
ADRA1A P35348 1/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18140498 0.86 TSHR (0.42) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C
SCHEMBL18141361 0.86 TSHR (0.42) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C
Lithium Ion SCHEMBL18139734 0.86 TSHR (0.42) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C
SCHEMBL18139362 0.86 TSHR (0.42) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C
Potassium Ion SCHEMBL18139644 0.86 TSHR (0.42) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C
SCHEMBL428693 0.86 SMN1; SMN2 (0.52) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C
SCHEMBL28853370 0.85 FABP3 (0.45) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C
SCHEMBL1260662 0.85 ADRA1D (0.57) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C
SCHEMBL529986 0.84 SMN1; SMN2 (0.46) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C
SCHEMBL1260814 0.83 ADRA1D (0.57) SMN1; SMN2ADRA1DPTAFRHTR1DHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9084739-B2 Cross-linked copolymer containing phosphorylcholine monomer and cosmetic composition containing same KCI LIMITED (KR) 2015-07-21 US claimed
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME KCI CO., LTD. (KR) 2014-09-25 US claimed
EP-2662070-A2 CROSS-LINKED COPOLYMER CONTAINING PHOSPHORYLCHOLINE MONOMER AND COSMETIC COMPOSITION CONTAINING SAME KCI Limited. (KR) 2013-11-13 EP claimed
US-20130295038-A1 Cross-Linked Copolymer Containing Phosphorylcholine Monomer and Cosmetic Composition Containing Same KCI LIMITED (KR) 2013-11-07 US claimed
US-8278097-B2 Method for forming embryoid bodies NOF CORPORATION (JP) 2012-10-02 US claimed
US-20090246871-A1 For forming embryoid bodies from embryonic stem (ES) cells easily and efficiently without complicated technique NOF CORPORATION (JP) 2009-10-01 US claimed
US-20060252148-A1 For forming embryoid bodies from embryonic stem (ES) cells easily and efficiently without complicated technique NOF CORPORATION (JP) 2006-11-09 US claimed
EP-0537972-B1 Treating solution for contact lenses NOF CORP (JP) 1996-07-10 EP claimed
US-5461433-A Cleaning contact lens by immersing in solution containing copolymer where one of the monomers contains phsophate and tertiary ammonium groups NOF CORPORATION (JP) 1995-10-24 US claimed
EP-0537972-A1 Treating solution for contact lenses NOF CORPORATION (JP) 1993-04-21 EP claimed
US-20240092043-A1 CONTACT LENS WITH A HYDROGEL COATING THEREON ALCON INC. (CH) 2024-03-21 US disclosed
EP-3896074-B1 METHOD, KIT, AND DEVICE FOR PREPARING GLYCAN FROM GLYCOPROTEIN AIST (JP) 2023-10-25 EP disclosed
US-20220017648-A1 Method, Kit, and Device for Preparing Glycan from Glycoprotein SUMITOMO BAKELITE CO., LTD. (JP) 2022-01-20 US disclosed
EP-3896074-A1 METHOD, KIT, AND DEVICE FOR PREPARING GLYCAN FROM GLYCOPROTEIN NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2021-10-20 EP disclosed
US-11136344-B2 Purification agent for sugar chain or glycopeptide, and use thereof SUMITOMO BAKELITE CO., LTD. (JP) 2021-10-05 US disclosed
US-20060252148-A1 For forming embryoid bodies from embryonic stem (ES) cells easily and efficiently without complicated technique NOF CORPORATION (JP) 2006-11-09 US disclosed
EP-1657302-A1 CONTAINER FOR GERM LAYER FORMATION AND METHOD OF FORMING GERM LAYER NOF CORPORATION (JP) 2006-05-17 EP disclosed
EP-0537972-B1 Treating solution for contact lenses NOF CORP (JP) 1996-07-10 EP disclosed
US-5461433-A Cleaning contact lens by immersing in solution containing copolymer where one of the monomers contains phsophate and tertiary ammonium groups NOF CORPORATION (JP) 1995-10-24 US disclosed
EP-0537972-A1 Treating solution for contact lenses NOF CORPORATION (JP) 1993-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME C1QBP, PCTP, CD59 SMN1; SMN2 4469/4885ADRA1D 2687/4885PTAFR 851/4885
US-20130295038-A1 Cross-Linked Copolymer Containing Phosphorylcholine Monomer and Cosmetic Composition Containing Same PHOSPHO1, SGMS1, SGMS2 SMN1; SMN2 2864/4885ADRA1D 2549/4885PTAFR 1310/4885
US-11136344-B2 Purification agent for sugar chain or glycopeptide, and use thereof FUT5, MANBA, MGAM SMN1; SMN2 3076/4885ADRA1D 3137/4885PTAFR 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.